4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
RemeGen Co., Ltd. (9995) operates in the Biotechnology industry and is headquartered in Yantai, China with about 3,145 employees. Its market capitalization is roughly HK$44 billion. In the fiscal year ended 2025-12-31, 9995 reported CNY 3.2B in revenue and CNY 710M in net income.
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
Interactive charts & full statements → Open the 9995 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 3.2B | CNY 1.7B | CNY 1.1B | CNY 768M | — |
| Gross Profit | CNY 2.8B | CNY 1.4B | CNY 823M | CNY 498M | — |
| Operating Income (EBIT) | CNY 156M | (CNY 1.4B) | (CNY 1.5B) | (CNY 1.1B) | — |
| Net Income | CNY 710M | (CNY 1.5B) | (CNY 1.5B) | (CNY 999M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 7.2B | CNY 5.5B | CNY 5.5B | CNY 6.0B | — |
| Total Liabilities | CNY 3.6B | CNY 3.5B | CNY 2.1B | CNY 1.0B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9995 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms